Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder characterized by progressive weakness and impaired sensory function due to damage to the myelin sheath of peripheral nerves. According to Yusuf A. Rajabally (2024), the worldwide prevalence of CIDP is estimated at about 3 per 100,000, with an incidence of less than 1 per 100,000 per year. Current therapies include corticosteroids, intravenous immunoglobulin (IVIg), plasma exchange, and emerging monoclonal antibody treatments. According to the chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline analysis by Expert Market Research, increasing research, novel biologics, and improved diagnostics are expected to drive significant growth in the coming years.
Major companies involved in the chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline analysis include Dianthus Therapeutics, Takeda, and others.
Leading drugs currently in the pipeline include DNTH103, NVG-2089, TAK-411, and others.
The pipeline growth for chronic inflammatory demyelinating polyneuropathy is being driven by increased clinical trials of novel biologics, rising investment in immunotherapies, and advancements in targeted monoclonal antibody development.
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis Report by Expert Market Research gives comprehensive insights into chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for chronic inflammatory demyelinating polyneuropathy (CIDP). The chronic inflammatory demyelinating polyneuropathy (CIDP) report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline landscape will include an analysis based on efficacy and safety measures outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with chronic inflammatory demyelinating polyneuropathy (CIDP) treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to chronic inflammatory demyelinating polyneuropathy (CIDP).
Read more about this report - Request a Free Sample
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare immune-mediated neurological disorder characterized by progressive damage to the myelin sheath surrounding peripheral nerves. It occurs when the immune system mistakenly attacks nerve coverings, leading to muscle weakness, numbness, tingling, and impaired motor functions.
Chronic inflammatory demyelinating polyneuropathy (CIDP) treatments include corticosteroids, intravenous immunoglobulin therapy, plasma exchange, and biologic therapies aimed at reducing immune-mediated nerve damage and improving functional mobility. In June 2024, the U.S. Food and Drug Administration approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for CIDP, marking a significant advancement in the drug pipeline by offering patients a targeted, subcutaneous treatment option.
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare but significant neurological disorder with considerable clinical impact worldwide. According to a recent study by Yusuf A Rajabally, 2024, the global prevalence is around 3 per 100,000, while the annual incidence is less than 1 per 100,000. According to Rare Disease Advisor, prognosis is influenced by age, disease subtype, and treatment response. While children often respond better but relapse more frequently, elderly patients show poorer recovery. Treatment benefits about 90% of patients, though relapse occurs in nearly 50%, with long-term studies reporting 1%-11% mortality and 2%-14% loss of ambulation.
This section of the report covers the analysis of chronic inflammatory demyelinating polyneuropathy (CIDP) drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, the phase III covers a major share of the total chronic inflammatory demyelinating polyneuropathy (CIDP) clinical trials, with 39%. It is followed by phase II at 33%, and phase IV at 12%. This distribution across clinical phases highlights steady advancements that can positively accelerate treatment innovations in the chronic inflammatory demyelinating polyneuropathy (CIDP) market.
The drug molecule categories covered under the chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline analysis include small molecules, monoclonal antibodies, gene therapies, polymers, and peptides. The chronic inflammatory demyelinating polyneuropathy (CIDP) report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for chronic inflammatory demyelinating polyneuropathy (CIDP). Immunotherapy-based drug classes are gaining significant importance in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) market. For example, in June 2024, the U.S. Food and Drug Administration approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), the first and only neonatal Fc receptor (FcRn) blocker for CIDP. This innovative therapy offers a novel mechanism of action, marking the first major advancement in CIDP treatment in more than 30 years.
The EMR report for the chronic inflammatory demyelinating polyneuropathy (CIDP) pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed chronic inflammatory demyelinating polyneuropathy (CIDP) therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in chronic inflammatory demyelinating polyneuropathy (CIDP) clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for chronic inflammatory demyelinating polyneuropathy (CIDP). It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of chronic inflammatory demyelinating polyneuropathy (CIDP) drug candidates.
DNTH103, sponsored by Dianthus Therapeutics, is under evaluation in a Phase 3 clinical study for chronic inflammatory demyelinating polyneuropathy (CIDP). This investigational monoclonal antibody is designed to selectively inhibit the active form of the C1s protein in the classical complement pathway, while preserving immune defense via other pathways. The trial is examining its efficacy, safety, and potential as a convenient, subcutaneous, self-administered therapy with dosing every two weeks.
NVG-2089, sponsored by Nuvig Therapeutics, Inc., is a recombinant human IgG1-Fc fusion protein that is being investigated in a Phase 2 study for chronic inflammatory demyelinating polyneuropathy (CIDP). The study is examining its safety, tolerability, and efficacy in patients. NVG-2089 is designed to mimic the immunomodulatory effects of intravenous immunoglobulin (IVIg) while offering improved consistency, scalability, and patient convenience. By selectively engaging anti-inflammatory pathways, it is being developed as a next-generation alternative to IVIg, aiming to overcome challenges of supply, tolerability, and administration.
TAK-411, sponsored by Takeda, is a hypersialylated immunoglobulin G (hsIgG) derived from human plasma and designed to enhance anti-inflammatory activity in patients with chronic inflammatory demyelinating polyneuropathy (CIDP). In this Phase 2 CASCA study, researchers are examining its efficacy, safety, and tolerability compared to a historical placebo group. The trial aims to evaluate whether TAK-411 improves physical functioning, reduces inflammation, and alleviates CIDP symptoms over a treatment duration of up to one year.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for chronic inflammatory demyelinating polyneuropathy (CIDP). It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into chronic inflammatory demyelinating polyneuropathy (CIDP) collaborations, regulatory environments, and potential growth opportunities.
Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market
Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market
North America Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market
Upto 30% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share